Funding agencies: This study was supported by CHDI, The Canadian Institutes for Health Research, and the Huntington Society of Canada. M.R.H. is a Killam University Professor and holds a Canada Research Chair in Human Genetics.
A systematic review and meta-analysis of clinical variables used in Huntington disease research
Article first published online: 18 OCT 2013
© 2013 Movement Disorder Society
Volume 28, Issue 14, pages 1987–1994, December 2013
How to Cite
Franciosi, S., Shim, Y., Lau, M., Hayden, M. R. and Leavitt, B. R. (2013), A systematic review and meta-analysis of clinical variables used in Huntington disease research. Mov. Disord., 28: 1987–1994. doi: 10.1002/mds.25663
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 9 DEC 2013
- Article first published online: 18 OCT 2013
- Manuscript Accepted: 11 AUG 2013
- Manuscript Revised: 24 JUN 2013
- Manuscript Received: 14 MAR 2013
- Huntington disease;
- clinical endpoint;
- disease severity
Treatment effect in Huntington disease (HD) clinical trials has relied on primary outcome measures such as total motor score or functional rating scales. However, these measures have limited sensitivity, particularly in pre- to early stages of the disease. We performed a systematic review of HD clinical studies to identify endpoints that correlate with disease severity. Using standard HD keywords and terms, we identified 749 published studies from 1993 to 2011 based on the availability of demographic, biochemical, and clinical measures. The average and variability of each measure was abstracted and stratified according to pre-far, pre-close, early, mild, moderate, and severe HD stages. A fixed-effect meta-analysis on selected variables was conducted at various disease stages. A total of 1,801 different clinical variables and treatment outcomes were identified. Unified Huntington Disease Rating Scale (UHDRS) Motor, UHDRS Independence, and Trail B showed a trend toward separation between HD stages. Other measures, such as UHDRS Apathy, Verbal Fluency, and Symbol Digit, could only distinguish between pre- and early stages of disease and later stages, whereas other measures showed little correlation with increasing HD stages. Using cross-sectional data from published HD clinical trials, we have identified potential endpoints that could be used to track HD disease progression and treatment effect. Longitudinal studies, such as TRACK-HD, are critical for assessing the value of potential markers of disease progression for use in future HD therapeutic trials. A list of variables, references used in this meta-analysis, and database is available at http://www.cmmt.ubc.ca/research/investigators/leavitt/publications. © 2013 International Parkinson and Movement Disorder Society